Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease

Acta Neurologica Scandinavica

Volumn 127, Issue 4, 2013, Pages 290-294

  Muller B ^a,b   Assmus, J ^a   Larsen, J P ^b,c   Haugarvoll, K ^a,b   Skeie, G O ^a,b   Tysnes, O B ^a,b   Alves, Guido ^d   Bjelland Forsaa, Elin ^d   Dreetz Gjerstad, Michaela ^d   Herlofson, Karen ^d   HogenEsch, Ineke ^d   Petter Larsen, Jan ^d   Müller, Bernd ^d   Freddy Pedersen, Kenn ^d   Olve Skeie, Geir ^d   Telstad, Wenche ^d   Tysnes, Ole Bjørn ^d   Vossius, Corinna ^d   Bruland, Britt ^d   Bruun, Siri ^d   Ellefseth, Marit ^d   Kari Haaland, Liv ^d   Kastet, Jane ^d   Kjærandsen, Marianne ^d   Laugaland, Anita ^d   Leiknes, Ingrid ^d   Lode, Kirsten ^d   Rasmussen, Kristina ^d   Arnevik Renså, Marit ^d   Tønnesen, Gro ^d   more..

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d NONE

Author keywords

Autonomic; Dopamine agonist; Epidemiology; Levodopa; Parkinson

Indexed keywords

ENTACAPONE; LEVODOPA; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOPAMINERGIC SYSTEM; DYSPHAGIA; FEMALE; FOLLOW UP; HUMAN; HYPERSALIVATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MOTOR DYSFUNCTION; ORTHOSTATIC BLOOD PRESSURE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; POPULATION BASED CASE CONTROL STUDY; SCORING SYSTEM; SUSTAINED DRUG RELEASE; SYSTOLIC BLOOD PRESSURE; UNIFIED PARKINSON DISEASE RATING SCALE; URINARY DYSFUNCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; COHORT STUDIES; DOPAMINE AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84875071119     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12010     Document Type: Article

References (34)

1. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-12.
2. Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord 2008;23:1428-34. Epub 2008/06/11.
3. Muller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB. Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. Mov Disord 2011;26:65-72. Epub 2010/10/07.
4. O'Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 2008;23:101-6.
5. Ferrer I. Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis. 2011;2011:708404. Epub 2011/03/16.
6. Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2007;13:323-32. Epub 2007/03/14.
7. Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, Hattori T. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm. 2008;115:443-60. Epub 2008/03/11.
8. Micieli G, Tosi P, Marcheselli S, Cavallini A. Autonomic dysfunction in Parkinson's disease. Neurol Sci. 2003;24(Suppl 1):S32-4. Epub 2003/05/30.
9. Cersosimo MG, Benarroch EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord 2008;23:1065-75. Epub 2008/04/30.
10. Jost WH. Gastrointestinal dysfunction in Parkinson's Disease. J Neurol Sci 2010;289:69-73. Epub 2009/09/01.
11. Hunter PC, Crameri J, Austin S, Woodward MC, Hughes AJ. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry 1997;63:579-83. Epub 1998/01/04.
12. Tumilasci OR, Cersosimo MG, Belforte JE, Micheli FE, Benarroch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson's disease. Mov Disord 2006;21:660-7. Epub 2006/01/19.
13. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn 2006;25:116-22.
14. Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci 2010;289:74-80. Epub 2009/09/11.
15. Alves G, Muller B, Herlofson K et al. Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009;80:851-7. Epub 2009/02/28.
16. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
17. Goetz CG, Tilley BC, Shaftman SR et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-70. Epub 2008/11/26.
18. Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res 1996;6:125-6. Epub 1996/04/01.
19. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DM, Liebermann A, eds. Recent development in Parkinson's disease. Florham Park, NJ: MacMillan Health Care Information, 1987;153-63.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-42. Epub 1967/05/01.
21. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002;287:455-63. Epub 2002/02/02.
22. Kim HJ, Park SY, Cho YJ et al. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci 2009;287:200-4. Epub 2009/08/25.
23. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, van Hilten JJ. Patient-reported autonomic symptoms in Parkinson disease. Neurology. 2007;69:333-41. Epub 2007/07/25.
24. Korchounov A, Kessler KR, Yakhno NN, Damulin IV, Schipper HI. Determinants of autonomic dysfunction in idiopathic Parkinson's disease. J Neurol 2005;252:1530-6. Epub 2005/12/20.
25. Sethi K. Levodopa unresponsive symptoms in Parkinson disease. Mov Disord 2008;23(Suppl 3):S521-33. Epub 2008/09/11.
26. Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology. 1989;39:1309-14. Epub 1989/10/01.
27. Ciucci MR, Barkmeier-Kraemer JM, Sherman SJ. Subthalamic nucleus deep brain stimulation improves deglutition in Parkinson's disease. Mov Disord 2008;23:676-83. Epub 2008/01/01.
28. Krogh K, Ostergaard K, Sabroe S, Laurberg S. Clinical aspects of bowel symptoms in Parkinson's disease. Acta Neurol Scand 2008;117:60-4. Epub 2007/12/22.
29. Witjas T, Kaphan E, Azulay JP et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology. 2002;59:408-13. Epub 2002/08/15.
30. Stowe RL, Ives NJ, Clarke C et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev. 2008;2:CD006564. Epub 2008/04/22.
31. Allcock LM, Kenny RA, Burn DJ. Clinical phenotype of subjects with Parkinson's disease and orthostatic hypotension: autonomic symptom and demographic comparison. Mov Disord 2006;21:1851-5.
32. Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin Auton Res 2005;15:76-82.
33. Camerlingo M, Ferraro B, Gazzaniga GC, Casto L, Cesana BM, Mamoli A. Cardiovascular reflexes in Parkinson's disease: long-term effects of levodopa treatment on de novo patients. Acta Neurol Scand 1990;81:346-8. Epub 1990/04/01.
34. Matinolli M, Korpelainen JT, Sotaniemi KA, Myllyla VV, Korpelainen R. Recurrent falls and mortality in Parkinson's disease: a prospective two-year follow-up study. Acta Neurol Scand 2011;123:193-200. Epub 2010/06/16.